AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Adaptimmune Therapeutics Stock Soars 14% on Portfolio Sale
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 29, 2025 7:11 am ET1min read
Aime SummaryAdaptimmune Therapeutics' stock surged 14% in pre-market trading on July 29, 2025, reflecting significant investor interest and potential market shifts.
Adaptimmune Therapeutics has recently made strategic moves that have impacted its stock performance. The company announced the sale of its cell therapy portfolio, including key assets like TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55 million. This decision is part of a broader restructuring effort aimed at optimizing the company's operations and financial health.
Following the announcement of the sale agreement, Adaptimmune's stock experienced a significant decline, trading down 65% to 12 cents per share early Monday afternoon. This drop was likely due to investor concerns about the company's future direction and the potential impact of the asset sale on its long-term prospects.
Despite the recent volatility, analysts remain optimistic about Adaptimmune's future. According to six analysts, the average rating for ADAP stock is "Buy," with a 12-month stock price target of $1.35, representing a potential increase of 1,250.00% from the latest trading price. This positive outlook suggests that investors may see value in the company's remaining assets and future growth potential.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
ECARX Holdings plunges 8.33% in pre-market trading on investor caution ahead of earnings report and sector volatility
Dec.23 2025
WhiteFiber Surged 9.38% in Pre-Market Trading on Strategic Sector Optimism
Dec.23 2025
Dave & Buster's Entertainment shares plunge 5.70% pre-market on mixed analyst signals and Q4 revenue contraction
Dec.23 2025
BlackSky Technology (BKSY) shares rise 13.61% pre-market as Jefferies initiates coverage with Buy rating and $23 price target
Dec.23 2025
SEALSQ Surges 5.24% in Pre-Market Trading on Investor Confidence and Sector Rotation
Dec.23 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet